The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2026 | Biallelic inactivation of KEAP1/STK11 predicts response to checkpoint blockade in NSCLC
Mark Jeng, MD, Memorial Sloan Kettering Cancer Center, New York, NY, shares insights into a study evaluating the role of gene zygosity of KEAP1/STK11 in response to checkpoint inhibition in patients with non-small cell lung cancer (NSCLC). KEAP1/STK11 biallelic inactivation was associated with better response to dual checkpoint blockade, in particular in patients with KEAP1 biallelic inactivation. In patients with monoallelic inactivation, no difference was seen between response to single versus dual checkpoint blockade, indicating that zygosity plays a role in response and should be a consideration when deciding whether to treatment patients with dual immune checkpoint blockade. This interview took place at the IASLC 2026 World Conference on Lung Cancer congress in Seoul, Republic of Korea.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
